A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom

Anthony Bentley (), Ivana Filipovic (), Katherine Gooch () and Katharina Büsch ()

Health Economics Review, 2013, vol. 3, issue 1, 1-12

Abstract: Palivizumab is cost-effective compared to no prophylaxis in the United Kingdom in many of the subgroups considered, showing that palivizumab would be a cost-effective use of National Health Service resources. Copyright Bentley et al.; licensee Springer. 2013

Keywords: Palivizumab; Prophylaxis; Cost-effectiveness; Respiratory syncytial virus; United Kingdom (search for similar items in EconPapers)
Date: 2013
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
http://hdl.handle.net/10.1186/2191-1991-3-18 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:3:y:2013:i:1:p:1-12:10.1186/2191-1991-3-18

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/2191-1991-3-18

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().